Opendata, web and dolomites

PMSMatTrain SIGNED

Novel Biomaterial-based Device for the Treatment of Progressive MS- - An Integrated Pan- European Approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PMSMatTrain project word cloud

Explore the words cloud of the PMSMatTrain project. It provides you a very rough idea of what is the project "PMSMatTrain" about.

talk    axonal    innovation    degenerative    entrepreneurship    translation    yield    oligodendrocyte    policy    mri    stage    neuroprotective    mechanisms    recruited    first    manufacturing    skills    jrtp    gaining    ibudilast    protocols    molecules    pms    multiple    functionalised    clinically    generate    education    quality    sclerosis    tool    esrs    time    basics    leadership    remyelination    modal    characterised    tested    gender    standardised    property    smes    neuroprotection    april    training    signals    dispersal    ms    employable    cultures    evaluation    drugs    drug    release    device    directed    anti    stem    proximal    hyaluronan    utilise    compulsory    commercialisation    medical    elusion    modifying    demyelination    complementary    scaled    cortex    model    organotypic    biomaterials    disease    progressive    neuroinflammation    inflammatory    mass    silico    industry    chronic    therapy    receive    miconazole    patient    spectrophotometry    cns    pathophysiology    transferable    molecular    intellectual    discipline    joint    small    affairs    biomimetic    cgmp    beneficiaries    spif    vivo    followed    immediately    arising    scaffolds    cross    cell    pmsmattrain    regulatory    weight    designed   

Project "PMSMatTrain" data sheet

The following table provides information about the project.

Coordinator
NATIONAL UNIVERSITY OF IRELAND GALWAY 

Organization address
address: UNIVERSITY ROAD
city: Galway
postcode: H91
website: www.nuigalway.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙962˙143 €
 EC max contribution 3˙962˙143 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2023-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NATIONAL UNIVERSITY OF IRELAND GALWAY IE (Galway) coordinator 1˙373˙421.00
2    UNIVERSITEIT ANTWERPEN BE (ANTWERPEN) participant 512˙640.00
3    WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER DE (MUENSTER) participant 505˙576.00
4    NEOS SURGERY SL ES (DONOSTIA SAN SEBASTIAN) participant 501˙809.00
5    SYDDANSK UNIVERSITET DK (ODENSE M) participant 297˙522.00
6    UNIVERSITE GRENOBLE ALPES FR (GRENOBLE) participant 274˙802.00
7    UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA IT (CHIETI) participant 261˙499.00
8    CONTIPRO AS CZ (DOLNI DOBROUC) participant 234˙871.00
9    UNIVERSITE GRENOBLE ALPES FR (SAINT MARTIN D'HERES) participant 0.00

Map

 Project objective

PMSMatTrain is focusing on gaining a comprehensive understanding of the progressive (late degenerative phase) of multiple sclerosis (PMS) from basics to translation, fully supported by 8 beneficiaries (6 research institutions, 2 SMEs). Recruited ESRs will receive compulsory discipline-specific, generic and complementary transferable skills training. PMSMatTrain’s Joint Research Education and Training programme (JRTP) will provide early stage researchers with high quality research and transferable skills training in intellectual property, leadership skills, innovation, regulatory affairs, entrepreneurship, gender policy, and medical device evaluation, which will ensure that they are immediately employable in industry. The consortium will develop a multi-modal hyaluronan-based medical device designed to release small molecular weight anti-inflammatory molecules (APRIL and sPIF) followed by remyelination and neuroprotective drugs (ibudilast and miconazole). PMSMatTrain will for the first time utilise these functionalised multi-modal biomimetic hyaluronan scaffolds as a tool to investigate cross-talk between signals arising due to chronic neuroinflammation and those leading to demyelination and axonal loss, while identifying molecular mechanisms that facilitate remyelination and neuroprotection in PMS. This approach could yield the first cortex-proximal and directed biomaterials-based disease-modifying therapy for PMS. These scaffolds will be tested in state of the art MS patient induced stem cell-derived oligodendrocyte cultures and organotypic cultures to investigate MS pathophysiology. In vivo responses will be characterised using field-leading MRI and mass spectrophotometry protocols. PMSMatTrain will also generate a clinically-relevant in silico model of drug elusion and dispersal within the CNS. Our industry partners will develop the end-device by providing standardised manufacturing protocols for scaled-up production and commercialisation of the cGMP product.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PMSMATTRAIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PMSMATTRAIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

GREAT (2019)

Grating Reflectors Enabled laser Applications and Training

Read More  

GMOS-Train (2020)

Global Mercury Observation and Training Network in Support to the Minamata Convention

Read More  

I-DireCT (2019)

Immune DIREcted and Cancer-selective immunoTherapy

Read More